caa a22 4500 469073632 CHVBK 20180323132928.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF01789020 doi (NATIONALLICENCE)springer-10.1007/BF01789020 A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro [Elektronische Daten] [Huaiyuan Jiao, Weiming Shen, Yuchiro Ohe, Kaoru Miura, Tomohide Tamura, Nagahiro Saijo] Summary: Activated by interferon γ (IFNγ)(50 U/ml) and lipopolysaccharide (50 ng/ml), mouse peritoneal macrophages were cocultured with the L1210 parental cell line (L1210/PRT) and its Adriamycin-, cisplatin-resistant cell lines (L1210/ADM, L1210/CDDP) for 24 h at effector: target (E:T) ratios of 10:1, 5:1 and 2:1. The direct 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT)-cleavage assay, a new improved indirect MTT assay, and the colony-formation assay were used to quantify macrophage-mediated suppression of these non-adherent tumour targets. The results showed that the macrophages can produce formazan at a high level, which can interfere with the final results of a direct MTT assay. The new indirect MTT assay can avoid such interference because the effectors are separated from the targets before the assay is performed, so the real viability of the targets is reflected. An indirect MTT assay, as developed in this study, could be better than the direct assay for examining the suppressive effect of activated macrophages on non-adherent tumour cells in vitro. This study also revealed that all the L1210 cell lines can be suppressed significantly by the macrophages at E:T ratios of 10:1 and 5:1 while the two drug-resistant cell lines have lower survival rates at an E:T ratio of 10:1, indicating that they are more susceptible than their parental cell line. Springer-Verlag, 1992 Macrophage nationallicence Cytotoxicity nationallicence Drug resistance nationallicence L1210 nationallicence Jiao Huaiyuan Department of Oral and Maxillofacial Surgery, College of Stomatology, West China University of Medical Sciences, China aut Shen Weiming Pharmacological Division, Sichuan Industrial Institute of Antibiotics, Chengdu, Sichuan, China aut Ohe Yuchiro Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut Miura Kaoru Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut Tamura Tomohide Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut Saijo Nagahiro Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/6(1992-11-01), 412-416 0340-7004 35:6<412 1992 35 262 https://doi.org/10.1007/BF01789020 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01789020 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jiao Huaiyuan Department of Oral and Maxillofacial Surgery, College of Stomatology, West China University of Medical Sciences, China aut NATIONALLICENCE 700 1- Shen Weiming Pharmacological Division, Sichuan Industrial Institute of Antibiotics, Chengdu, Sichuan, China aut NATIONALLICENCE 700 1- Ohe Yuchiro Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut NATIONALLICENCE 700 1- Miura Kaoru Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut NATIONALLICENCE 700 1- Tamura Tomohide Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut NATIONALLICENCE 700 1- Saijo Nagahiro Dept. of Internal Medicine, National Cancer Center Research Institute, Tokyo, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/6(1992-11-01), 412-416 0340-7004 35:6<412 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer